A Study of Belimumab in Subjects With Systemic Lupus Erythematosus

Completed · Phase 3 · Has a placebo group

Conditions studied: Systemic Lupus Erythematosus

In brief

The purpose of this study is to evaluate the efficacy, safety, tolerability, and impact on quality of life of two different doses of belimumab administered in addition to standard therapy in subjects with active, autoantibody-positive systemic lupus erythematosus (SLE) disease.

Key facts

Study ID
NCT00410384
Run by
Human Genome Sciences Inc.
People needed
819
Starts
2006-12-01
Expected to finish
2010-03-01
Last updated by the study team
2017-02-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.